It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Eisai Files Fycompa in Europe for Pediatric Use
February 14, 2019
- MSD Files Keytruda/Inlyta Combo in Japan as 1st-Line Therapy for RCC
February 14, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- Takeda’s Adcetris Gets European OK for 1st-Line Stage IV Hodgkin’s Lymphoma
February 13, 2019
- Astellas/Pfizer Unveil Positive Xtandi Data for Hormone-Sensitive Prostate Cancer
February 13, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Xofluza Top Seller in Japan in January: Encise Snapshot
February 12, 2019
- Mochida Seeks Label Expansion for Dinagest in Japan
February 12, 2019
- Pfizer Initiates Voluntary Recall of Exforge Generics after Discovery of Carcinogenic Substances Above Limits
February 12, 2019
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
- Ethical Drug Sales Down 4.5% in December: Crecon
February 8, 2019
- SymBio Targets 11.8 Billion Yen Sales in 2022 under New 4-Year Biz Plan
February 8, 2019
- Torii Aims to Turn Profit in 2022, Forecasting Revenue Drop after Gilead HIV Pact Ends
February 8, 2019
- Torii to Sell Futhan to Nichi-Iko after 43% Off-Patent Price Slash
February 7, 2019
- Goichi Matsuda Named as New President of Torii
February 7, 2019
- Torii Launches Early Retirement Program as Part of Restructuring Plan
February 7, 2019
- Daiichi Sankyo’s Cancer Med Pexidartinib Gets Priority Review in US
February 7, 2019
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction
February 7, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…